Boston Scientific Corporation (BSX) : Bollard Group reduced its stake in Boston Scientific Corporation by 21.71% during the most recent quarter end. The investment management company now holds a total of 26,069,966 shares of Boston Scientific Corporation which is valued at $582,663,740 after selling 7,228,725 shares in Boston Scientific Corporation , the firm said in a disclosure report filed with the SEC on May 9, 2016.Boston Scientific Corporation makes up approximately 48.23% of Bollard Group’s portfolio.
Other Hedge Funds, Including , Ngam Advisors boosted its stake in BSX in the latest quarter, The investment management firm added 3,022 additional shares and now holds a total of 46,378 shares of Boston Scientific Corporation which is valued at $1,021,707. Boston Scientific Corporation makes up approx 0.02% of Ngam Advisors’s portfolio. United Asset Strategies added BSX to its portfolio by purchasing 101,945 company shares during the most recent quarter which is valued at $2,245,848. Boston Scientific Corporation makes up approx 0.98% of United Asset Strategies’s portfolio.Quantitative Investment Management boosted its stake in BSX in the latest quarter, The investment management firm added 101,500 additional shares and now holds a total of 281,600 shares of Boston Scientific Corporation which is valued at $6,203,648. Boston Scientific Corporation makes up approx 0.29% of Quantitative Investment Management’s portfolio. Burt Wealth Advisors sold out all of its stake in BSX during the most recent quarter. The investment firm sold 288 shares of BSX which is valued $6,313.
Boston Scientific Corporation opened for trading at $22 and hit $22.36 on the upside on Friday, eventually ending the session at $22.35, with a gain of 1.36% or 0.3 points. The heightened volatility saw the trading volume jump to 1,68,08,385 shares. Company has a market cap of $30,326 M.
On the company’s financial health, Boston Scientific Corporation reported $0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.24. The company had revenue of $1964.00 million for the quarter, compared to analysts expectations of $1912.86 million. The company’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.
Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by RBC Capital Mkts on Apr 28, 2016 to “Outperform”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Stifel on Apr 28, 2016 to “Buy”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Wedbush on Apr 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $19 .
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.